Xiang Xie
3 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer (NCT05976893) | Xiang Xie | 2023-08-01 |
Track Xiang Xie automatically
Every clearance here is in the API, with alerts when new ones post.